Literature DB >> 27872459

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke.

Hertzel Gerstein, Roman Jaeschke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27872459     DOI： 10.20452/pamw.3612

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


× No keyword cloud information.
  2 in total

1.  Adverse Drug Events Associated with Low-Dose (10 mg) Versus High-Dose (25 mg) Empagliflozin in Patients Treated for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Xia Dai; Zu-Chun Luo; Lu Zhai; Wen-Piao Zhao; Feng Huang
Journal:  Diabetes Ther       Date:  2018-03-09       Impact factor: 2.945

2.  First cardiovascular event in patients with type 2 diabetes mellitus of a cardiovascular risk management program of a poor Colombian population: a cohort study.

Authors:  Pablo Miranda-Machado; Fernando Salcedo-Mejía; Justo Paz Wilches; Juan Fernandez-Mercado; Fernando De la Hoz-Restrepo; Nelson Alvis-Guzmán
Journal:  BMC Cardiovasc Disord       Date:  2019-01-08       Impact factor: 2.298
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.